Ensuring Pediatric Medicine Safety: The Need for a Robust Regulatory Framework for India's Children
Following the deaths of children linked to contaminated cough syrups, there is an urgent call to reform the regulatory framework for pediatric medicines in India. Children are not 'small adults'; their physiological responses to drugs differ significantly, yet many dosages are currently extrapolated from adult guidelines. The article emphasizes the need for specific pediatric clinical trials and stricter oversight by the Central Drugs Standard Control Organisation (CDSCO). It advocates for a holistic framework to monitor medicine use, better pharmacovigilance, and the adoption of the WHO’s Essential Medicine List for children to ensure affordable and safe healthcare for the younger population.
Key Points
- Children require specific drug formulations and dosages because their pharmacodynamic responses differ from those of adults.
- Article 39(f) of the Indian Constitution mandates the state to ensure children are protected against exploitation and given opportunities for healthy development.
- India lacks a specific policy or legislation for pediatric drug research, often relying on general guidelines or adult data extrapolation.
- The World Health Organization (WHO) has issued several warnings regarding contaminated cough syrups manufactured in India that led to deaths globally.
Exam Facts
- Article 39(f) of the Constitution is a Directive Principle of State Policy related to child welfare.
- The Central Drugs Standard Control Organisation (CDSCO) is the primary regulatory body for drugs in India.
- The WHO introduced the first Essential Medicine List for children (EMLc) in 2007.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.